在阿尔茨海默病中解锁认知分析潜力 临床试验:研究用于分析新测量爆发设计数据的层次线性模型
Guoqiao Wang1,2, Jason Hassenstab1, Yan Li1
1Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Statistics in medicine
|November 25, 2024
概括
新的层次模型有效地分析通过测量爆发设计收集的复杂阿尔茨海默病试验数据. 这些先进的方法比分析常见认知测试结果的传统方法提供了更大的统计能力.
科学领域:
- 生物统计学 生物统计学
- 临床试验方法论 临床试验方法论
- 神经科学数据分析 神经科学数据分析
背景情况:
- 测量爆发设计在阿尔茨海默病 (AD) 试验中收集频繁的认知数据,提供高统计能力.
- 传统的统计方法难以应对爆发式设计产生的大量数据.
- 需要新的分析方法来有效分析AD临床试验数据.
研究的目的:
- 引入和评估用于分析测量爆发设计数据的新型层次线性混合效应模型.
- 在阿尔茨海默氏症临床试验中,与传统方法相比,证明这些新模型的效率.
- 为模拟和分析提供可访问的代码,以支持方法的开发.
主要方法:
- 对重复测量应用等级线性混合效应模型和等级混合模型的应用.
- 使用SAS程序Hpmixed进行数据分析.
- 通过模拟和真实世界阿尔茨海默病临床试验数据的验证.
主要成果:
- 与传统模型相比,等级模型在分析测量爆发设计数据方面表现出更高的效率.
- 提出的方法有效地处理突发设计的特征的大型数据集.
- SAS Hp混合程序促进了这些先进的分析技术的实施.
结论:
- 新的层次模型提供了一种更有效和更强大的方法来分析阿尔茨海默病临床试验中的测量爆发设计数据.
- 这些方法解决了大量数据集在爆发设计中所带来的计算挑战.
- 开发的分析框架和代码可以推进临床试验数据分析的统计方法.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.2K
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
2.9K
相关概念视频
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
